SCHEMBL5153067

SCHEMBL5153067

CC(C)(C)SCCN1C(=O)CSC1c1ccc2c(c1)OCCO2

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
MGAM O43451 1/20 0.45
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPK1 P28482 2/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
KCNA5 P22460 1/20 0.41
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151517 0.78 PTGS1 (0.51) ALDH1A1PTGS1PTGS2
SCHEMBL5156337 0.78 ACHE (0.63)
SCHEMBL5152753 0.77 PTGS1 (0.43) PTGS1PTGS2SMN1; SMN2KCNA5
SCHEMBL5152223 0.77 PTGS2 (0.50) PTGS1PTGS2
SCHEMBL5149599 0.74 HCRTR1 (0.46) PTGS1PTGS2SMN1; SMN2MAPK1KCNA5
SCHEMBL5149746 0.72 MGAM (0.56) ALDH1A1MGAMSMN1; SMN2HSD17B10USP2
SCHEMBL5151382 0.69 ALDH1A1 (0.54) ALDH1A1MGAMSMN1; SMN2HSD17B10MAPK1
SCHEMBL5149502 0.68 MGAM (0.56) ALDH1A1MGAMPTGS1PTGS2SMN1; SMN2
SCHEMBL5155489 0.67 ALDH1A1 (0.56) ALDH1A1MGAMPTGS1PTGS2SMN1; SMN2
SCHEMBL5156963 0.65 ALDH1A1 (0.52) ALDH1A1MGAMSMN1; SMN2HSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 ALDH1A1 3381/4885MGAM 2524/4885PTGS1 892/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I ALDH1A1 1370/4885MGAM 3677/4885PTGS1 2564/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I ALDH1A1 1370/4885MGAM 3677/4885PTGS1 2564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.